ZLDAF (Zelira Therapeutics) Quality Rank


ZLDAF Zelira Therapeutics Ltd ZLDAF
9 GF Score
Price $0.30
GF Value $0.06
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Zelira Therapeutics Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Zelira Therapeutics Quality Rank Related Terms

ZLDAF
9GF Score
Zelira Therapeutics Ltd ZLDAF
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Zelira Therapeutics (ZLDAF) Overvalued in 2026?

Based on GuruFocus' analysis, Zelira Therapeutics stock appears to be overvalued. The current stock price of $0.30 is trading 400% above its estimated GF Value™ of $0.06. GuruFocus considers Zelira Therapeutics to be Significantly Overvalued.

Key valuation signals for ZLDAF:

  • Quality Rank:
  • GF Value™: $0.06 vs. price of $0.30 (400% above fair value)
  • GF Score™: 9/100 with 7 warning signs

No single metric tells the full story. See the ZLDAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zelira Therapeutics Business Description

Address 101 St George’s Terrace, Level 3, Perth, WA, AUS, 6000
Zelira Therapeutics Ltd is a biotechnology company focused on developing a range of cannabinoid-based formulations for the treatment of various medical conditions in Australia. The company is involved in a human clinical trial program focused on insomnia, autism, and eczema, and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer. The company is organised into two operating segments based on geographic location of operations: Australia and United States of America.
9GF Score

Get the complete analysis for ZLDAF

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.30
Price
$0.06
GF Value